BioNexus Gene Lab (BGLC) Cash & Current Investments (2018 - 2026)

BioNexus Gene Lab (BGLC) has 9 years of Cash & Current Investments data on file, last reported at $4.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 89.76% year-over-year to $4.0 million; the trailing twelve-month figure through Mar 2026 stood at $4.0 million (up 89.76% YoY), and the FY2025 full-year result was $4.0 million, down 28.89% from the prior year.
• Cash & Current Investments fell to $4.0 million in Q1 2026, from $4.0 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $5.8 million in Q1 2024 to a low of $1.3 million in Q2 2022.
• A 5-year average of $3.2 million and a median of $2.9 million in 2025 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments soared 221.75% in 2023 and sank 64.17% in 2025, its largest moves.
• Tracing BGLC's Cash & Current Investments over 5 years: stood at $2.1 million in 2022, then surged by 113.21% to $4.5 million in 2023, then gained by 25.75% to $5.7 million in 2024, then retreated by 28.89% to $4.0 million in 2025, then fell by 1.85% to $4.0 million in 2026.
• Business Quant data shows BGLC's Cash & Current Investments at $4.0 million in Q1 2026, $4.0 million in Q4 2025, and $2.9 million in Q3 2025.